Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NEK2 | P51955 | 4/20 | 0.36 |
| ▸ | ADK | P55263 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2500547 | 0.88 | KCNH2 (0.43) | ATRKCNH2PREPNEK2CHEK1 | |
| SCHEMBL12198450 | 0.83 | ATR (0.43) | ATRKCNH2PREPNEK2CHEK1 | |
| SCHEMBL2502121 | 0.83 | ATR (0.49) | ATRNEK2 | |
| SCHEMBL2506364 | 0.82 | ATR (0.42) | ATRKCNH2PREPNPC1ADK | |
| SCHEMBL2507103 | 0.81 | PRKDC (0.42) | ATRKCNH2NEK2 | |
| SCHEMBL2500375 | 0.81 | ADK (0.44) | ATRKCNH2PREPNEK2ADK | |
| SCHEMBL12198441 | 0.79 | ATR (0.52) | ATRKCNH2CYP2A6NEK2ADK | |
| SCHEMBL2506338 | 0.78 | PREP (0.43) | ATRPREPNPC1NEK2 | |
| SCHEMBL29903476 | 0.78 | PREP (0.43) | ATRPREPNPC1NEK2 | |
| SCHEMBL2504524 | 0.78 | RAB9A (0.43) | ATRKCNH2PREPNPC1NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9075058-B2 | Coelenterazine analogues and coelenteramide analogues | JNC CORPORATION (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9075058-B2 | Coelenterazine analogues and coelenteramide analogues | JNC CORPORATION (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9056840-B2 | Coelenterazine analogues and coelenteramide analogues | JNC CORPORATION (JP) | 2015-06-16 | — | — | US | disclosed |
| US-9056840-B2 | Coelenterazine analogues and coelenteramide analogues | JNC CORPORATION (JP) | 2015-06-16 | — | — | US | disclosed |
| US-20150153344-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | JNC CORP (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150153344-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | JNC CORP (JP) | 2015-06-04 | — | — | US | disclosed |
| US-8883432-B2 | Coelenterazine analogues and coelenteramide analogues | JNC CORPORATION (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8883432-B2 | Coelenterazine analogues and coelenteramide analogues | JNC CORPORATION (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20140316137-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | JNC CORP (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140316137-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | JNC CORP (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140120538-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140120538-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2014-05-01 | — | — | US | disclosed |
| US-8642281-B2 | Coelenterazine analogues and coelenteramide analogues | JNC CORPORATION (JP) | 2014-02-04 | — | — | US | disclosed |
| US-8642281-B2 | Coelenterazine analogues and coelenteramide analogues | JNC CORPORATION (JP) | 2014-02-04 | — | — | US | disclosed |
| US-20110244481-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | JNC CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20110244481-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | JNC CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140120538-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | CCKAR, SI, GLP1R | ATR 4715/4885KCNH2 217/4885CYP2A6 2535/4885 |
| US-20140316137-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | CCKAR, SI, GLP1R | ATR 4796/4885KCNH2 251/4885CYP2A6 2732/4885 |
| US-20110244481-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | CCKAR, SI, GLP1R | ATR 4715/4885KCNH2 217/4885CYP2A6 2535/4885 |
| US-20150153344-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | CCKAR, SI, GLP1R | ATR 4715/4885KCNH2 217/4885CYP2A6 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.